Furthermore, the treatment of Her2-enriched breast cancer cells with a STAT3 inhibitor alone demonstrated a significant reduction in cancer cell survival, suggesting a likely benefit of STAT3 inhibitor monotherapy for this subset of patients, whereas basal-like breast cancer patients would possibly benefit from LDHC-targeted therapy. This evidence concerns the gene ERBB2 and breast cancer.